18F-4FMFES与18F-FDG PET/CT在雌激素受体阳性子宫内膜癌中的初步报告
该II期临床试验初步比较了雌激素受体靶向示踪剂18F-4FMFES与18F-FDG PET/CT在25例ER阳性子宫内膜癌或子宫内膜上皮内瘤变患者中的表现,并尝试用药物干预减少18F-4FMFES肠道本底。结果显示丁溴东莨菪碱可显著降低肠道本底体积,18F-4FMFES的肿瘤本底比显著高于18F-FDG,两者均适用于检测ER阳性子宫内膜癌。
要点
- 丁溴东莨菪碱重复静脉注射可显著减少18F-4FMFES肠道本底体积。
- 18F-4FMFES肿瘤SUVmax为3.0–14.4(9.4±3.2),18F-FDG为0–22.0(7.5±5.1)。
- 18F-4FMFES肿瘤本底比(16.4±5.4)显著高于18F-FDG(7.4±4.6)。
核心结论
- 使用丁溴东莨菪碱可改善18F-4FMFES腹部本底。
- 18F-FDG与18F-4FMFES PET均适用于检测ER阳性子宫内膜癌,但18F-4FMFES肿瘤对比度更好。
研究设计与样本
- 正在进行的II期临床试验初步报告,纳入25例经病理证实的ER阳性子宫内膜癌或子宫内膜上皮内瘤变患者。
- 患者随机顺序在2周内分别接受18F-FDG和18F-4FMFES PET/CT显像。
主要发现
- 18F-4FMFES肿瘤SUVmax范围为3.0至14.4(9.4±3.2),18F-FDG SUVmax范围为0至22.0(7.5±5.1)。
- 18F-4FMFES肿瘤本底比为16.4±5.4,显著高于18F-FDG的7.4±4.6。
- 在18F-4FMFES摄取和对比度、18F-FDG摄取以及18F-FDG/18F-4FMFES摄取比值方面,1级与更高级别肿瘤间观察到显著差异。
关键数值与推荐
- 18F-4FMFES PET图像中,勾画覆盖全腹部并排除肝、膀胱和子宫的兴趣区,应用SUV阈值大于4。
- 患者在接受18F-4FMFES示踪剂注射前口服4 mg洛哌丁胺,或在18F-4FMFES PET/CT期间重复静脉注射20 mg丁溴东莨菪碱。
临床怎么用
- 对于ER阳性子宫内膜癌,可考虑使用18F-4FMFES PET/CT以获得更好的肿瘤对比度。
- 进行18F-4FMFES PET/CT时,可采用丁溴东莨菪碱重复静脉注射以减少肠道本底。
局限性
- 本文为初步报告,样本量有限。
- 研究正在进行中,最终结论尚待完整数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article reports the preliminary results of a phase II clinical trial investigating the use of the estrogen receptor (ER)-targeting PET tracer 4-fluoro-11β-methoxy-16α-18F-fluoroestradiol (18F-4FMFES) and 18F-FDG PET in endometrial cancers. In parallel, noninvasive interventions were attempted to slow progression of 18F-4FMFES metabolites in the intestines to reduce abdominal background uptake. Methods: In an ongoing study, 25 patients who received prior pathologic confirmation of an ER-positive endometrial cancer or endometrial intraepithelial neoplasia agreed to participate in the ongoing clinical trial. Patients were scheduled for 18F-FDG and 18F-4FMFES PET/CT imaging in random order and within 2 wk. Patients were administered either 4 mg of loperamide orally before 18F-4FMFES tracer injection or repeated intravenous injection of 20 mg of hyoscine N-butylbromide during 18F-4FMFES PET/CT. Regions of interest covering the whole abdomen and excluding the liver, bladder, and uterus were drawn for the 18F-4FMFES PET images, and an SUV threshold of more than 4 was applied. The volume of the resulting region was compared between the different interventions to estimate the extent of the intestinal background uptake. Results: Repeated injection of hyoscine N-butylbromide substantially reduced the intestinal background volume, whereas loperamide had a significant but moderate effect. 18F-4FMFES tumor SUVmax ranged from 3.0 to 14.4 (9.4 ± 3.2), whereas 18F-FDG SUVmax ranged from 0 to 22.0 (7.5 ± 5.1). Tumor-to-background ratio was significantly higher for 18F-4FMFES (16.4 ± 5.4) than for 18F-FDG (7.4 ± 4.6). Significant differences were observed between grade 1 and higher-grade tumors concerning 18F-4FMFES uptake and contrast, 18F-FDG uptake, and the 18F-FDG/18F-4FMFES uptake ratio. Conclusion: It is possible to improve 18F-4FMFES abdominal background using hyoscine N-butylbromide. Both 18F-FDG and 18F-4FMFES PET are suitable for detection of ER-positive endometrial cancers, although 18F-4FMFES yielded a better tumor contrast than did 18F-FDG.
引用
- Paquette M, Espinosa-Bentancourt E, Lavallée É, et al. 18F-4FMFES and 18F-FDG PET/CT in Estrogen Receptor-Positive Endometrial Carcinomas: Preliminary Report. J Nucl Med. 2021. PMID: 34413142. doi:10.2967/jnumed.121.262617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。